Observational studyMedicine2025
Serum magnesium levels and their association with sleep quality and disease severity in fibromyalgia syndrome: An observational cross-sectional study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia syndrome (FMS) is a multifactorial condition characterized by chronic widespread pain, fatigue, and sleep disturbances, often accompanied by biochemical and psychosocial alterations. Sleep quality plays a critical role in disease severity and patient functionality. Recent evidence suggests that magnesium may influence both pain and sleep regulation. This observational cross-sectional study aimed to investigate the relationship between sleep quality and serum magnesium levels in patients with FMS and to explore their associations with clinical characteristics such as pain severity and functional status. Eighty-two patients diagnosed with FMS were grouped based on their Pittsburgh Sleep Quality Index (PSQI) scores: PSQI ≤ 5 (n = 27) and PSQI > 5 (n = 55). Demographic and clinical parameters, including age, body mass index, tender points, Fibromyalgia Impact Questionnaire (FIQ), and serum magnesium levels, were compared between the groups. Correlation analyses were performed to assess associations between magnesium levels and clinical variables. No significant differences were found between the groups in terms of age and body mass index (P > .05 for all). The PSQI > 5 group demonstrated significantly higher tender points (P = .035), visual analog scale scores (P = .002), FIQ scores (P < .001), and lower serum magnesium levels (P = .038) compared to the PSQI ≤ 5 group. Significant negative correlations were observed between magnesium levels and tender points (ρ = -0.293, P = .008), visual analog scale score (ρ = -0.252, P = .023), FIQ scores (ρ = -0.242, P = .028), PSQI scores (ρ = -0.324, P = .003). The findings indicate that lower serum magnesium levels are associated with poorer sleep quality, higher pain severity, and greater functional impairment in patients with FMS. These findings suggest a potential link between magnesium levels and the pathophysiology of sleep disturbances in FMS. However, due to the cross-sectional nature of the study and possible confounding influences, further longitudinal and interventional research is required to determine whether magnesium supplementation could offer clinical benefits in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.